


**SAFC**<sup>®</sup>

Pharma/Biopharma Raw Materials



PARTECK<sup>®</sup> ODT EXCIPIENT

# RIGHT HERE RIGHT NOW

Combining rapid disintegration with exceptional strength for your ODT formulation.

Parteck<sup>®</sup> ODT is an excipient allowing for a simplified production of orally disintegrating tablets.

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

**Millipore  
SIGMA**

# Parteck® ODT Excipient

**Convenience for the patient.  
And for you.**

Many patients prefer the convenience and speed of orally disintegrating tablets (ODTs). By providing fast-acting medication, ODTs allow you to add value to existing compounds and extend your product life cycles. Our Parteck® ODT excipient is directly compressible and contains two ingredients: spray-granulated D-Mannitol and croscarmellose sodium – both comply with the main pharmacopoeias. The excipient facilitates the production of robust, pleasant-tasting tablets that rapidly disintegrate and dissolve across a broad range of hardnesses and compression forces. Parteck® ODT excipient is easy on your budget, easy on your equipment, and easy to formulate and handle, while meeting the highest standards in production reliability and product quality.

## PARTECK® ODT EXCIPIENT PROVIDES:


-  Rapid disintegration with pleasant taste and mouth feel for patient compliance
-  Fast dissolution for rapid relief
-  Cost-effective development and production thanks to direct compressibility
-  Exceptionally hard tablets leading to simplified formulation work and handling
-  High dilution potential – allows up to 50% active ingredients in DC formulations

## Rapid disintegration.


Whether you need soft or hard tablets, high or low compaction – the choice is yours with Parteck® ODT excipient. It enables you to produce tablets that “melt” quickly and smoothly across a wide range of different production parameters, such as tablet hardnesses (Fig. 3). Thanks to its unique filamentous particle structure (Fig. 1) which remains even throughout compression and its greatly increased surface area, Parteck® ODT excipient supports high levels of safety and flexibility for your ODT development and production.

## Fast dissolution.

While other ODTs may disintegrate fast, too, they do not necessarily release the active ingredient immediately (Fig. 4). However, to help your formulation succeed, with Parteck® ODT excipient your active ingredients are released quickly and taste pleasant, too – for the convenience of patients.




**Fig. 1: Morphology of Parateck® ODT excipient powder (magnification 2000x).**




**Fig. 2: Compression profile of placebos with Parateck® ODT excipient vs. competitors.**

1% Mg stearate, Korsch EK 0 DMS, 500 mg tablets, diameter 11 mm, flat, faceted, tablet hardness by ERWEKA TBH 30 MD



**Fig. 3: Disintegration profile of API formulation with Parateck® ODT excipient vs. competitors.**

200 mg ibuprofen + 1% SiO<sub>2</sub> + 1% Mg stearate, Korsch EK 0 DMS, 500 mg tablets, diameter 11 mm, flat, faceted, USP disintegration in water at 37 °C



**Fig. 4: In-vitro dissolution profile of API formulation with Parateck® ODT excipient vs. competitors.**

200 mg ibuprofen + 1% SiO<sub>2</sub> + 1% Mg stearate (500 mg final weight) (Procedure: USP apparatus 2, 900 mL phosphate buffer, pH 7.2, 37 °C, 50 rpm, 221 nm)

### General formulation with Parateck® excipients

Active Ingredient (non DC)	0 – 50 %
100490 Parateck® ODT excipient	Ad 100 %
100663 Parateck® LUB excipient	1 – 1.5 %
100895 Sucralose	0.5 – 1.5 %
Flavor	0.5 %

**Table 1: The exemplary formulation above should give good results for a variety of drugs. Our application laboratory will gladly assist you with specific formulation challenges.**

## Directly compressible.

As Parateck® ODT excipient is designed for direct compression, it helps you produce tablets more cost-effectively. With its unique surface structure (Fig. 1), it also minimizes wear and tear on your equipment and leads to robust tablets with extremely low friability. Thanks to the high compressibility (Fig. 2) of Parateck® ODT excipient, active ingredients can account for up to 50 % of your formulation.

## The Emprove® Program.

Ensuring the compliance of your pharma and bio-pharma products involves the compilation of a vast amount of data, which can be time- and resource-intensive. In order to facilitate and accelerate this process, we developed our Emprove® Program. It includes 400 pharma raw and starting materials and a selection of filtration and single-use products. Each product in the portfolio is complemented with three different types of dossiers supporting you throughout the different stages of your operations: qualification, risk assessment, and process optimization – all designed to help you speed your way through the regulatory maze.

Find out more at:

**[EMDMillipore.com/emprove](https://EMDMillipore.com/emprove)**

Click. Explore.  
Learn more.

## PARTECK® PRODUCT PORTFOLIO

Excipients for oral solid dosage forms featuring unique particle properties and outstanding individual functionalities such as solubility enhancement or controlled release.

For more information, visit:

[EMDMillipore.com/pardeck](http://EMDMillipore.com/pardeck)

## FORMULATION PRODUCT FINDER APP

Find the right product for specific applications at:

[EMDMillipore.com/formulationapp](http://EMDMillipore.com/formulationapp)

## Need lubrication?

Pardeck® LUB is a range of stearates for consistent lubrication performance.

## Ordering information

Cat. No.	Product	Pack size
1.00490.1000	Pardeck® ODT EMPROVE® ESSENTIAL	1 kg PE bottle with screw cap
1.00490.9025	Pardeck® ODT EMPROVE® ESSENTIAL	25 kg PE carton box

The typical technical data above serve to generally characterize the excipient. These values are not meant as specifications and they do not have binding character. The product specification is available separately, from the website: [EMDMillipore.com](http://EMDMillipore.com)

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

For additional information, please visit [EMDMillipore.com](http://EMDMillipore.com)

To place an order or receive technical assistance, please visit [EMDMillipore.com/contactPS](http://EMDMillipore.com/contactPS)

